The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

XDS

Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463

Refinement of Macromolecular Structures by the Maximum-Likelihood Method

Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796

MOLREP : an Automated Program for Molecular Replacement

Vagin, A. A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,756

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,930

Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function

Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816

An updated patent review of Mcl-1 inhibitors (2020–2022)

Liu, J., Yin, F., Wang, Z., Song, T., & Zhang, Z. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2219394 · Cited by 13

Macrocyclic-based strategy in drug design: From lab to the clinic

Jin, X., Ding, N., Guo, H., & Hu, Q. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116733 · Cited by 13

Discovery of Novel Mcl-1 Inhibitors with a 3-Substituted-1 H -indole-1-yl Moiety Binding to the P1–P3 Pockets to Induce Apoptosis in Acute Myeloid Leukemia Cells

Deng, H., Zhang, J., Liu, L., Zhang, H., Han, Y. K., Wu, L., Jing, Y., Huang, M., & Zhao, L. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00643 · Cited by 13

BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress

Varkaris, A. S., Wang, K., Nouri, M., Kozlova, N. V., Schmidt, D. R., Stavridi, A.-M., Arai, S., Ambrosio, N., Poluben, L., Jiménez‐Vacas, J. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60238-x · Cited by 13

Seeking Convergence and Cure with New Myeloma Therapies

Choudhry, P., Galligan, D. C., & Wiita, A. P. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.005 · Cited by 13

Targeting Protein Neddylation to Inactivate Cullin-RING Ligases by Gossypol: A Lucky Hit or a New Start?

Yu, Q., & Sun, Y. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s286373 · Cited by 13

Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC

Faux, M. C., Weinstock, J., Gogos, S., Prato, E., Azimpour, A. I., O’Keefe, R. N., Cathcart‐King, Y., Garnham, A. L., Ernst, M., Preaudet, A., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0105 · Cited by 13

Chromosome 1 instability in multiple myeloma: Aberrant gene expression, pathogenesis, and potential therapeutic target

Luo, S., Su, T., Zhou, X., Hu, W., & Hu, J. (2022) · The FASEB Journal · doi:10.1096/fj.202200354 · Cited by 15

Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma

Jacob, M., Wiedemann, S., Brücher, D., Pieper, N. M., Birkhold, M., Särchen, V., Jeroch, J., Demes, M. C., Gretser, S., Braun, Y., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02430-8 · Cited by 13

B‐cell lymphoma‐2 family proteins in the crosshairs: Small molecule inhibitors and activators for cancer therapy

Gong, Q., Wang, H., Zhou, M., Zhou, L., Wang, R., & Li, Y. (2023) · Medicinal Research Reviews · doi:10.1002/med.21999 · Cited by 13

Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations

Henz, K., Al-Zebeeby, A., Başoğlu, M., Fulda, S., Cohen, G. M., Varadarajan, S., & Vogler, M. (2018) · Biological Chemistry · doi:10.1515/hsz-2018-0233 · Cited by 13

Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic Responses?

Barillé‐Nion, S., Lohard, S., & Juin, P. P. (2020) · Biomolecules · doi:10.3390/biom10081109 · Cited by 16

Targeting the B-cell lymphoma 2 anti-apoptotic proteins for cervical cancer treatment

Rahman, S. F. A., Lian, B. S. X., & Mohana‐Kumaran, N. (2020) · Future Oncology · doi:10.2217/fon-2020-0389 · Cited by 13

An expert overview of emerging therapies for acute myeloid leukemia: novel small molecules targeting apoptosis, p53, transcriptional regulation and metabolism

Saxena, K., & Konopleva, M. Y. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1804856 · Cited by 13

Co-targeting MCL-1 and ERK1/2 kinase induces mitochondrial apoptosis in rhabdomyosarcoma cells

Winkler, M., Friedrich, J., Boedicker, C., & Dolgikh, N. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101313 · Cited by 13

Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1

Lupták, J., Biśta, M., Fisher, D. I., Flavell, L., Gao, N., Wickson, K. F., Kazmirski, S. L., Howard, T. D., Rawlins, P. B., & Hargreaves, D. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798319014116 · Cited by 13

Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia

Vecchia, S. L., Doshi, S., Antonoglou, P., Kundu, T., Al-Santli, W., Avrampou, K., Witkowski, M. T., Pellattiero, A., Magrin, F., Ames, K. T., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx8662 · Cited by 12

Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma

Algarín, E. M., Quwaider, D., Campos-Laborie, F. J., Díaz-Tejedor, A., Mogollón, P., Vuelta, E., Martín-Sánchez, M., San‐Segundo, L., González-Méndez, L., Gutierrez, N. C., et al. (2021) · Cells · doi:10.3390/cells10030559 · Cited by 12

Host-derived growth factors drive ERK phosphorylation and MCL1 expression to promote osteosarcoma cell survival during metastatic lung colonization

McAloney, C. A., Makkawi, R., Budhathoki, Y., Cannon, M. V., Franz, E., Gross, A. C., Cam, M., Vetter, T. A., Duhen, R., Davies, A. E., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00867-w · Cited by 12

Differential expression pattern of Bcl-2 family members in B and T cells in systemic lupus erythematosus and rheumatoid arthritis

Kielbassa-Elkadi, K., van der Weele, L., Voskuyl, A. E., de Vries, N., Eldering, E., & Kuijpers, T. W. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03203-7 · Cited by 12

Therapy-induced senescence in prostate cancer: mechanisms, therapeutic strategies, and clinical implications

Bacca, L. F. G., Brandariz, J., Zacchi, F., Zivi, A., Mateo, J., & Labbé, D. P. (2025) · Gene · doi:10.1016/j.gene.2025.149774 · Cited by 12

Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors

Senichkin, V. V., Pervushin, N. V., Zamaraev, A. V., Sazonova, E. V., Zuev, A. P., Streletskaia, A. Y., Prikazchikova, T. A., Zatsepin, T. S., Kovaleva, O. V., Tchevkina, E. M., et al. (2021) · Cancers · doi:10.3390/cancers14010181 · Cited by 12

Stayin’ alive: BCL-2 proteins in the hematopoietic system

Zehnle, P. M. A., Wu, Y., Pommerening, H., & Erlacher, M. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.03.006 · Cited by 12

Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma

Parrondo, R. D., Paulus, A., & Ailawadhi, S. (2022) · Cancers · doi:10.3390/cancers14143330 · Cited by 12

Synthetic Retinoid Kills Drug‐Resistant Cancer Stem Cells via Inducing RARγ‐Translocation‐Mediated Tension Reduction and Chromatin Decondensation

Zhang, Y., Dong, Q., An, Q., Zhang, C., Mohagheghian, E., Niu, B., Qi, F., Wei, F., Chen, S., Chen, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202203173 · Cited by 12

Development of Potent Mcl-1 Inhibitors: Structural Investigations on Macrocycles Originating from a DNA-Encoded Chemical Library Screen

Hekking, K. F. W., Maroto, S., van Kekem, K., Haasjes, F. S., Slootweg, J. C., Alink, P. G. B. O., Dirks, R. P., Sardana, M., Bolster, M. G., Kuijpers, B. H. M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02206 · Cited by 12

MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells

Tada, M., Sumi, T., Tanaka, Y., Hirai, S., Yamaguchi, M., Miyajima, M., Niki, T., Takahashi, H., Watanabe, A., & Sakuma, Y. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.014 · Cited by 12

A one-step tRNA-CRISPR system for genome-wide genetic interaction mapping in mammalian cells

Zhao, Y., Tyrishkin, K., Sjaarda, C. P., Khanal, P., Stafford, J., Rauh, M. J., Liu, X., Babak, T., & Yang, X. (2019) · Scientific Reports · doi:10.1038/s41598-019-51090-3 · Cited by 12

Using CETSA assay and a mathematical model to reveal dual Bcl-2/Mcl-1 inhibition and on-target mechanism for ABT-199 and S1

Guo, Z., Song, T., Xue, Z., Liu, P., Zhang, M., Zhang, X., & Zhang, Z. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105105 · Cited by 12

Impact of BH3-mimetics on Human and Mouse Blood Leukocytes: A Comparative Study

Rohner, L., Reinhart, R., Iype, J. M., Bachmann, S., Kaufmann, T., & Fux, M. (2020) · Scientific Reports · doi:10.1038/s41598-019-57000-x · Cited by 12

Dual inhibition of anti-apoptotic proteins BCL-XL and MCL-1 enhances cytotoxicity of Nasopharyngeal carcinoma cells

Rahman, S. F. A., Azlan, A., Lo, K. W., Azzam, G., & Mohana‐Kumaran, N. (2022) · Discover Oncology · doi:10.1007/s12672-022-00470-9 · Cited by 12

LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers

Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58753-y · Cited by 11

Constitutive High Expression of NOXA Sensitizes Human Embryonic Stem Cells for Rapid Cell Death

Basundra, R., Kapoor, S., Hollville, É., Kiapour, N., Lopez, A. B., Melchiorre, N. M., & Deshmukh, M. (2021) · Stem Cells · doi:10.1093/stmcls/sxab008 · Cited by 11

SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma

Portelinha, A., Wang, S., Parsa, S., Jiang, M., Gorelick, A. N., Mohanty, S., Sharma, S., de Stanchina, E., Berishaj, M., Zhao, C., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20231143 · Cited by 11

The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges

Avigan, Z. M., Mitsiades, C. S., & Laganà, A. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.10.001 · Cited by 11

Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma

Chang, Y., Chen, M., Yeh, C., & Hsiao, M. (2020) · Biomolecules · doi:10.3390/biom10101377 · Cited by 11

Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA

Fairchild, C. K., Floros, K. V., Jacob, S., Coon, C. M., Puchalapalli, M., Hu, B., Harada, H., Dozmorov, M. G., Koblinski, J. E., Smith, S. C., et al. (2021) · Cancers · doi:10.3390/cancers13102310 · Cited by 11

CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1

Yakymiv, Y., Augeri, S., Bracci, C., Marchisio, S., Aydin, S., D’Ardìa, S., Massaia, M., Ferrero, E., Ortolan, E., & Funaro, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-00733-5 · Cited by 11

Hypericin, a potential new BH3 mimetic

Doroshenko, A., Tomková, S., Kožár, T., & Štroffeková, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.991554 · Cited by 11

EVA1A regulates hematopoietic stem cell regeneration via ER-mitochondria mediated apoptosis

Liu, B., Zhou, Y., Wu, Q., Fu, Y., Zhang, X., Wang, Z., Yi, W., Wang, H., Chen, Z., Song, Z., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05559-9 · Cited by 11

The Cytoprotective Role of Autophagy in Response to BRAF-Targeted Therapies

Elshazly, A. M., & Gewirtz, D. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914774 · Cited by 12

Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma

Lu, Y., Huang, H., Yang, H., Chen, D., Wu, S., Zhou, J., & Wang, R. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1329066 · Cited by 11

NOXA-dependent contextual synthetic lethality of BCL-XL inhibition and “osmotic reprogramming” in colorectal cancer

Knoll, G., Riffelsberger, P., Raats, D., Kranenburg, O., & Ehrenschwender, M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2446-8 · Cited by 13

Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy

Zoeller, J. J., Press, M. F., Selfors, L. M., Dering, J., Slamon, D. J., Hurvitz, S. A., & Brugge, J. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251163 · Cited by 11

Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment

Soncini, D., Martinuzzi, C., Becherini, P., Gelli, E., Ruberti, S., Todoerti, K., Mastracci, L., Contini, P., Cagnetta, A., Laudisi, A., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.279276 · Cited by 11

A constitutive BCL2 down-regulation aggravates the phenotype of PKD1-mutant-induced polycystic kidney disease

Duplomb, L., Droin, N. M., Bouchot, O., Thauvin‐Robinet, C., Bruel, A., Thévenon, J., Callier, P., Meurice, G., Pata-Merci, N., Loffroy, R., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx349 · Cited by 11

An ERG Enhancer–Based Reporter Identifies Leukemia Cells with Elevated Leukemogenic Potential Driven by ERG-USP9X Feed-Forward Regulation

Aqaqe, N., Yassin, M., Yassin, A. A., Ershaid, N., Katz-Even, C., Zipin‐Roitman, A., Kugler, E., Lechman, E. R., Gan, O. I., Mitchell, A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3215 · Cited by 11

Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-XL and BCL-2

Roy, M. J., Vom, A., Okamoto, T., Smith, B. J., Birkinshaw, R. W., Yang, H. J., Abdo, H., White, C. A., Segal, D., Huang, D. C. S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01771 · Cited by 11

MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3+ regulatory T cells

Teh, C. E., Robbins, A. K., Henstridge, D. C., Dewson, G., Diepstraten, S. T., Kelly, G. L., Febbraio, M. A., Gabriel, S. S., O’Reilly, L. A., Strasser, A., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0585-1 · Cited by 10

LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway

Lee, I., Doepner, M., Weissenrieder, J., Majer, A. D., Mercado, S., Estell, A., Natale, C. A., Sung, P. J., Foskett, J. K., Carroll, M. P., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0478 · Cited by 10

A necroptotic-to-apoptotic signaling axis underlies inflammatory bowel disease

Pang, J., Al‐Ani, A., Patel, K. M., Zhou, Y., Young, S. N., Chen, J., Kong, I. Y., Barrios, M. H., Rickard, J. A., Chen, S., et al. (2026) · Science · doi:10.1126/science.aeh7112 · Cited by 10

Deciphering molecular specificity in MCL-1/BAK interaction and its implications for designing potent MCL-1 inhibitors

Wei, H., Wang, H., Xiang, S., Wang, J., Qu, L., Chen, X., Guo, M., Lu, X., & Chen, Y. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01454-2 · Cited by 10

Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies

Chong, S. J. F., Lai, J. X. H., Iskandar, K. B., Leong, B. J., Wang, C., Wang, Y., Guièze, R., Raman, D., Lim, R. H. F., Wu, C. J., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02694-4 · Cited by 10

Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target

Breunis, W. B., Brack, E. K., Ehlers, A. C., Bechtold, I., Kisele, S., Wurth, J., Mous, L., Zabėlė, D., Steffen, F. D., Zahnow, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62629-6 · Cited by 10

Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma

Schneller, A., Zojer, N., Bolomsky, A., & Ludwig, H. (2021) · Haematologica · doi:10.3324/haematol.2020.277152 · Cited by 10

Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer

Liu, D., Hou, X., Wu, W., Zanfagnin, V., Li, Y., Correia, C., Zhao, Z., Zhao, C., Liu, Z., Zhang, T., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04073-0 · Cited by 10

MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia

Manzano-Muñoz, A., Alcon, C., Menéndez, P. R., Ramírez, M. R., Seyfried, F., Debatin, K., Meyer, L. H., Samitier, J., & Montero, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.695225 · Cited by 10

Caseinolytic protease P (CLPP) activated by ONC201 inhibits proliferation and promotes apoptosis in human epithelial ovarian cancer cells by inducing mitochondrial dysfunction

Kou, X., Ding, H., Li, L., & Chao, H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4321 · Cited by 10

Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics

Mukherjee, N., Dart, C. R., Amato, C. M., Honig-Frand, A., Lambert, J. R., Lambert, K. A., Robinson, W. A., Tobin, R. P., McCarter, M. D., Couts, K. L., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.11.035 · Cited by 10

Development of a series of novel Mcl-1 inhibitors bearing an indole carboxylic acid moiety

Deng, H., Huang, M., Liu, H., Zhang, H., Liu, L., Gao, B., Li, X., Li, J., Niu, Q., Zhang, Z., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106018 · Cited by 10

Transient targeting of BIM-dependent adaptive MCL1 preservation enhances tumor response to molecular therapeutics in non-small cell lung cancer

Shi, K., Lu, H., Zhang, Z., Fu, Y., Wu, J., Zhou, S., Ma, P., Ye, K., Zhang, S., Shi, H., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01064-2 · Cited by 10

A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells

Zhao, T., He, Q., Xie, S., Zhan, H., Jiang, C., Lin, S., Liu, F., Wang, C., Chen, G., & Zeng, H. (2023) · Molecular Medicine · doi:10.1186/s10020-022-00565-7 · Cited by 10

Eltrombopag directly activates BAK and induces apoptosis

Chen, M., Hu, L., Bao, X., Ye, K., Li, Y., Zhang, Z., Kaufmann, S. H., Xiao, J., & Dai, H. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05918-6 · Cited by 11

Intracellular BAPTA directly inhibits PFKFB3, thereby impeding mTORC1-driven Mcl-1 translation and killing MCL-1-addicted cancer cells

Sneyers, F., Kerkhofs, M., Speelman-Rooms, F., Welkenhuyzen, K., Rovere, R. L., Shemy, A., Voet, A. R. D., Eelen, G., Dewerchin, M. A., Tait, S. W. G., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06120-4 · Cited by 10

Intracellular BH3 Profiling Reveals Shifts in Antiapoptotic Dependency in Human B Cell Maturation and Mitogen-Stimulated Proliferation

Dai, J., & Luftig, M. A. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701473 · Cited by 10

Induction of the BIM Short Splice Variant Sensitizes Proliferating NK Cells to IL-15 Withdrawal

Jacobs, B., Pfefferle, A., Clement, D., Berg‐Larsen, A., Sætersmoen, M., Lorenz, S., Wiiger, M. T., Goodridge, J. P., & Malmberg, K. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1801146 · Cited by 10

Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia

Smith, V. M., Lomas, O., Constantine, D., Palmer, L., Schuh, A., Bruce, D., Gonchar, O., Macip, S., Jayne, S., Dyer, M. J. S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000917 · Cited by 10

Hypertonicity counteracts MCL‐1 and renders BCL‐XL a synthetic lethal target in head and neck cancer

Heimer, S., Knoll, G., Neubert, P., Hammer, K. P., Wagner, S., Bauer, R. J., Jantsch, J., & Ehrenschwender, M. (2020) · FEBS Journal · doi:10.1111/febs.15492 · Cited by 10

Pharmacological targeting of c-FLIPL and Bcl-2 family members promotes apoptosis in CD95L-resistant cells

König, C., Hillert-Richter, L. K., Ivanisenko, N. V., Иванисенко, В. А., & Lavrik, I. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-76079-1 · Cited by 10

Absence of pro-survival A1 has no impact on inflammatory cell survival in vivo during acute lung inflammation and peritonitis

Gangoda, L., Schenk, R. L., Best, S. A., Nedeva, C., Louis, C., D’Silva, D. B., Fairfax, K. A., Jarnicki, A., Puthalakath, H., Sutherland, K. D., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00839-3 · Cited by 10

Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma

Spaan, I., Timmerman, L. M., Kimman, T., Slomp, A., Cuenca, M., van Nieuwenhuijzen, N., Moesbergen, L. M., Minnema, M. C., Raymakers, R. A. P., & Peperzak, V. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003624 · Cited by 10

Hypertonicity-imposed BCL-XL addiction primes colorectal cancer cells for death

Heimer, S., Knoll, G., Steixner, C., Calance, D. N., Trinh, D. T., & Ehrenschwender, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.035 · Cited by 10

BCL‐XL exerts a protective role against anemia caused by radiation‐induced kidney damage

Brinkmann, K., Waring, P., Glaser, S. P., Wimmer, V. C., Cottle, D. L., Tham, M. S., Nhu, D., Whitehead, L. W., Delbridge, A. R. D., Lessène, G., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2020105561 · Cited by 10

The prognostic significance of MCL1 copy number gain in esophageal squamous cell carcinoma

Xu, C., Liu, Y., Huang, J., Wang, H., Tan, L., Xu, Y., Jiang, Z., Wang, X., Hou, Y., Jiang, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21181 · Cited by 10

Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability

Tantawy, S. I., Timofeeva, N., Hernández, A., Sarkar, A. K., & Gandhi, V. V. (2023) · Oncotarget · doi:10.18632/oncotarget.28440 · Cited by 10

De novo discovery of a molecular glue–like macrocyclic peptide that induces MCL1 homodimerization

Li, F., Zhang, M., Liu, C., Cheng, J., Yang, Y., Peng, X., Li, Z., Cai, W., Yu, H., Wu, J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2426006122 · Cited by 9

Targeting MCL‐1 to Overcome Therapeutic Resistance and Improve Cancer Mortality

Mohiuddin, M. (2025) · Health Science Reports · doi:10.1002/hsr2.71390 · Cited by 9

The tumor suppressor LACTB remodels mitochondria to promote cytochrome c release and apoptosis

Kamerkar, S. C., Kang, T., Stan, R. V., Usherwood, E. J., & Higgs, H. N. (2025) · Science Advances · doi:10.1126/sciadv.adx7809 · Cited by 9

Inhibition of oligomeric BAX by an anti-apoptotic dimer

Newman, C. E., Gygi, M. A., Alimohamadi, H., DeAngelo, T. M., Camara, C. M., Mintseris, J., Yu, E., Harvey, E. P., Hauseman, Z. J., Fan, L., et al. (2025) · Cell · doi:10.1016/j.cell.2025.10.037 · Cited by 9

Upregulation of Mcl-1S Causes Cell-Cycle Perturbations and DNA Damage Accumulation

Streletskaia, A. Y., Senichkin, V. V., Prikazchikova, T. A., Zatsepin, T. S., Zhivotovsky, B., & Kopeina, G. S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.543066 · Cited by 9

A small natural molecule CADPE kills residual colorectal cancer cells by inhibiting key transcription factors and translation initiation factors

Zheng, G., Tang, M., Shu, C., Xin, W., Zhang, Y., Chi, B.-B., Shi, M., Guo, X., Zhang, Z., & Lian, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03191-5 · Cited by 9

AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death

Jia, J., Ji, W., Saliba, A. N., Csizmar, C. M., Ye, K., Hu, L., Peterson, K. L., Schneider, P. A., Meng, X. W., Venkatachalam, A., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01283-9 · Cited by 9

A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1

Zhao, K., Braun, M., Meyer, L., Otte, K., Raifer, H., Helmprobst, F., Möschl, V., Pagenstecher, A., Urban, H., Ronellenfitsch, M. W., et al. (2024) · Cells · doi:10.3390/cells13070632 · Cited by 9

Don’t fear the reaper: The role of regulated cell death in tumorigenesis and BH3-mimetics for cancer therapy

Marca, J. E. L., Kelly, G. L., Strasser, A., & Diepstraten, S. T. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.06.018 · Cited by 9

Hypertonicity primes malignant melanoma cells for apoptosis

Calance, D. N., Steixner, C., Groß, S., Schuler‐Thurner, B., Knoll, G., & Ehrenschwender, M. (2018) · APOPTOSIS · doi:10.1007/s10495-018-1446-y · Cited by 9

A redox switch regulates the structure and function of anti-apoptotic BFL-1

Korshavn, K. J., Wales, T. E., Bird, G. H., Engen, J. R., & Walensky, L. D. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0458-9 · Cited by 9

Future Developments in the Treatment of AL Amyloidosis

Theodorakakou, F., Fotiou, D., Dimopoulos, M. A., & Kastritis, E. (2022) · Hemato · doi:10.3390/hemato3010012 · Cited by 9

Discovery of novel biaryl sulfonamide based Mcl-1 inhibitors

Follows, B., Fessler, S. P., Baumeister, T., Campbell, A.-M., Zablocki, M.-M., Li, H., Gotur, D., Wang, Z., Zheng, X., Molz, L., et al. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.06.008 · Cited by 9

Concomitant targeting of Hedgehog signaling and MCL-1 synergistically induces cell death in Hedgehog-driven cancer cells

Meister, M. T., Boedicker, C., Linder, B., Kögel, D., Klingebiel, T. E., & Fulda, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.08.012 · Cited by 9

Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells

Thijssen, R., Álvarez-Díaz, S., Grace, C. S., Gao, M., Segal, D., Xu, Z., Strasser, A., & Huang, D. C. S. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0576-2 · Cited by 9

Computational Design of BH3-Mimetic Peptide Inhibitors That Can Bind Specifically to Mcl-1 or Bcl-X L : Role of Non-Hot Spot Residues

Reddy, C. N., Manzar, N., Ateeq, B., & Sankararamakrishnan, R. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00661 · Cited by 9

BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia

Parry, N., Busch, C., Assmann, V. D., Cassels, J. E., Hair, A., Helgason, G. V., Wheadon, H., & Copland, M. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01211-1 · Cited by 9

X-ray co-crystal structure of compound 20 with Mcl-1

Huang, X., & Whittington, D. A. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6udi/pdb · Cited by 9

Comparative Analysis of the Techniques for the Determination of Binding Affinity between a Small Molecule Inhibitor and a Protein TargetPreprint

Luo, Y., & Chen, Y. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.16.594462 · Cited by 9

Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo

Ji, Y., Harris, M. A., Newton, L. M., Harris, T. J., Fairlie, W. D., Lee, E. F., & Hawkins, C. J. (2024) · BMC Cancer · doi:10.1186/s12885-024-13088-7 · Cited by 8

BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies

Markouli, M., Pagoni, M. N., & Diamantopoulos, P. T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1501950 · Cited by 8

Sesamin Induces MCL-1-Dependent Apoptosis in Activated T Cells and Ameliorates Experimental Atopic Dermatitis

Park, H.-S., Sung, W. J., Park, Y.-Y., Hong, J., Oh, H. K., & Lee, H. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.116753 · Cited by 9

Factors affecting response and resistance to venetoclax in acute myeloid leukemia

Diamantidis, M. D. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1577908 · Cited by 8

Study of the Bcl-2 Interactome by BiFC Reveals Differences in the Activation Mechanism of Bax and Bak

Gonzalo, Ó., Benedi, A., Vela, L., Anel, A., Naval, J., & Marzo, I. (2023) · Cells · doi:10.3390/cells12050800 · Cited by 8

A1 is induced by pathogen ligands to limit myeloid cell death and NLRP3 inflammasome activation

Speir, M., Tye, H., Gottschalk, T. A., Simpson, D. S., Djajawi, T. M., Deo, P., Ambrose, R. L., Conos, S. A., Emery, J., Abraham, G., et al. (2023) · EMBO Reports · doi:10.15252/embr.202356865 · Cited by 8

MCL1 Can Be Targeted to Induce Apoptosis in Multiple Cancer Types

(2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2016-207

Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models

Maragno, A. L., Mistry, P., Kotschy, A., Szlavik, Z., Murray, J., Davidson, J. E. P., Toumelin-Braizat, G. L., Chanrion, M., Bruno, A., Clapéron, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4482 · Cited by 15

Development and Characterization of Novel Mcl-1 Inhibitors for Treatment of Cancer.

Mady, A. S. A. (2016) · Deep Blue (University of Michigan) · Cited by 1

Targeting MCL-1 in cancer: current status and perspectives

Wang, H., Guo, M., Wei, H., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01079-1 · Cited by 318

Targeting MCL‐1 to Overcome Therapeutic Resistance and Improve Cancer Mortality

Mohiuddin, M. (2025) · Health Science Reports · doi:10.1002/hsr2.71390 · Cited by 9